title: SPM-927 (Schwarz Pharma).
abstract: Schwarz Pharma, under license from Harris FRC, is developing SPM-927, synthesized by researchers at the University of Houston, for the potential treatment of epilepsy and neuropathic pain.
authors.affiliation: The Cleveland Clinic Foundation, Departments of Neurology/Pharmacy, 9500 Euclid Ave-S51, Cleveland, OH 44195, USA. cahovinga@aol.com
authors.forename: Collin A
authors.initials: CA
authors.lastname: Hovinga
mesh_terms: D000577:Amides / Q000737:chemistry* / Q000627:therapeutic use*; D000700:Analgesics / Q000737:chemistry* / Q000627:therapeutic use*; D000818:Animals; D000927:Anticonvulsants / Q000737:chemistry* / Q000627:therapeutic use*; D002986:Clinical Trials as Topic / Q000706:statistics & numerical data; D006801:Humans; D011407:Propane / Q000031:analogs & derivatives / Q000737:chemistry* / Q000627:therapeutic use*; D013678:Technology, Pharmaceutical / Q000331:legislation & jurisprudence / Q000379:methods*
chemical_list: D000577:Amides; D000700:Analgesics; D000927:Anticonvulsants; C476828:2-(acetylamino)-3-methoxy-N-(phenylmethyl)-, (2R)-; D011407:Propane